Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.51% to HK$5.33, with a turnover of HK$396.03 million.
The Zhitong Finance App learned that Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.51% to HK$5.33, with a turnover of HK$396.03 million.
According to the news, Nuochengjianhua announced that the BCL2 inhibitor ICP-248 and the Bruton tyrosine kinase (BTK) inhibitor obutinib independently developed by the company have been clinically approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in China. According to reports, ICP-248 and obutinib are important assets of the company with global competitiveness in the field of hematoma, and a number of clinical studies have been carried out in China and the US.
Furthermore, on March 11, Nuochengjianhua announced that the latest phase 2 clinical data on the treatment of severe atopic dermatitis (AD) with the novel TYK2 inhibitor ICP-332 will be released in the form of a major oral report at the 2024 American Academy of Dermatology annual meeting. ICP-332 is a highly selective oral TYK2 inhibitor. Previously, its phase 2 clinical study to treat severe atopic dermatitis had reached a major end.